Health Literacy in Medicines Use and Pharmacy: A Definitive Guide
Sold by Books Puddle, New York, NY, U.S.A.
AbeBooks Seller since 22 November 2018
New - Soft cover
Condition: New
Ships within U.S.A.
Quantity: 3 available
Add to basketSold by Books Puddle, New York, NY, U.S.A.
AbeBooks Seller since 22 November 2018
Condition: New
Quantity: 3 available
Add to basketHealth Literacy in Medicines Use and Pharmacy: A Definitive Guide highlights issues related to medication literacy from the context of the pharmacist and other healthcare professionals. This definitive guide will undoubtedly serve as an invaluable resource for healthcare professionals in training and practice, fostering excellence in patient care globally. The book provides a clear explanation of medication literacy, presents different tools to assess health and medication literacy, readability, and comprehensibility of written medicine information (WMI), and elaborates on different approaches to develop customized and patient-friendly WMI. The book also covers health and medication literacy in special populations, including geriatrics, pediatrics, and pregnant/lactating patients. Written by experts in health communication, this book will help pharmacists, other health professionals, educators, students, and regulators, who need to develop customized educational materials that can be understood by a broad range of patients, especially those with low health literacy.
Prof. Ahmed Awaisu is a Professor of Clinical Pharmacy & Practice. He is currently the Head of the Department of Clinical Pharmacy and Practice in the College of Pharmacy at Qatar University. His research interest includes outcome-based research, pharmacoepidemiology and medication safety, pharmacy education, and health promotion. Prof. Awaisu has established a medication use optimization research niche using generous funds from Qatar University, Qatar National Research Fund, Hamad Medical Corporation, and other agencies. He has been involved in mentoring PhD, MSc, and undergraduate research projects related to prescribing/deprescribing, medication adherence, medication safety, quality of life, and other health-related outcomes.
Prof. Ahmed Awaisu was the former Associate Editor of Value in Health Regional Issue (CEWAA). He was also the Section Editor (Clinical Pharmacy) for the Elsevier-published textbook entitled “Encyclopedia of Pharmacy Practice and Clinical Pharmacy”. He was also the former Chair of the Qatar University Institutional Review Board.
Prof. Awaisu was the recipient of the “Qatar University Merit Award for Outstanding Faculty” in September 2017 and the “Qatar University Research Excellence Award in Medical, Biomedical and Health Sciences” in April 2019. He was also the recipient of the “Best New Investigator Award” by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) during the 14th Annual ISPOR European Conference in Madrid, Spain in November 2011. He has served as the WHO Lead Consultant for reviewing the health system development in some countries. He is a member of the American College of Clinical Pharmacy (ACCP), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), among others.
The scholar is a very passionate and outstanding scholar whose vision is to make sustainable impact in the society through grooming competent healthcare professionals, mentoring novice researchers, high-impact innovative research, and advancing healthcare.
Dr. Emad Eldin Munsour holds a PhD degree in Pharmacy Practice from Universiti Sains Malaysia and has around 21 years in Pharma-regulatory and compliance area. He looks after the authorization of pharmaceutical products, including evaluation of bioequivalence studies, clinical trials, and Pharmacovigilance system, in addition to CMC (Chemistry, Manufacturing, and Controls). Dr. Emad is the editor of Qatar National Formulary (QNF) and is a professional reviewer for the WHO bulletin and Value in Health Regional issues. He is also involved in many projects related to Qatar National Health Strategy (NHS), including, the National Drug Coding, Generic use and advancement of the pharmaceutical legislative framework. He participated in the activities of National Pharmacovigilance Center (Associate Member of Uppsala Monitoring Center, WHO).
Dr. Emad is currently leading the national pharmaceutical track and trace project in Qatar and actively engaged in GS1 implementation in the healthcare sector; he is also engaged in the development and implementation of national medicines security strategy. Emad is a member of the working group for the establishment of policies and mandates for regulating national pharmaceuticals related Digital Health/e-Health data and interoperability standards.
His research interest in the area of health and medication literacy, drug and poisons information services quality of life and patient reported outcome; he shared his research in various international conferences and published several articles on pharmaceutical care and other pharmacy practice areas.
Parisa Aslani, BPharm(Hons), MSc, GradCertEdStud (Higher Ed), PhD, MRPharmS, FPS, FFIP, FANZCAP, is a Professor in Medicines Use Optimisation at The University of Sydney, Australia. She is known internationally for her research in the areas of consumer medicines information and adherence to therapy. Her research has impacted policy and education in the healthcare sector, and at the Australian Government level, and has led to a global initiative on developing medicine information strategies for implementation at national and local levels. Her research skills range from qualitative techniques to survey design and randomized control trials.
Dr. Rabia Hussain is a Senior Lecturer at the School of Pharmaceutical Sciences, Universiti Sains Malaysia, located in Penang. She is a renowned researcher in the field of medicine safety, pharmacovigilance, medication adherence, and clinical pharmacy. Her research has been published in high-impact journals and focuses on pharmacovigilance, research methods in pharmacy practice, clinical pharmacy, and issues related to medicines use.
Dr. Hussain has collaborated with ReAct - Action on Antibiotic Resistance and Health Action International, Asia Pacific, to improve the use of antibiotics. She is the Section Editor for the Journal of Pharmaceutical Policy and Practice (JoPPP) and has edited "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy (Elsevier)". Dr. Hussain is a fellow of the Royal Society for Public Health, and she has been nominated as the Apex Young Scholar by Universiti Sains Malaysia.
With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing.
Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category”. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: z.babar@hud.ac.uk
"About this title" may belong to another edition of this title.
We accept return for those books which are received damamged. Though we take appropriate care in packaing to avoid such situation.
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to Books Puddle, New York, New York, U.S.A., without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
| Order quantity | 12 to 19 business days | 12 to 14 business days |
|---|---|---|
| First item | £ 2.95 | £ 5.17 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.